Welcome!

News Feed Item

Global Markets for Generic Drugs

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Global Markets for Generic Drugs

https://www.reportbuyer.com/product/2009161/Global-Markets-for-Generic-Drugs.html

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018; these are based on industry sources and a considered assessment of the regulatory environment, healthcare policies, demographics and other factors that directly affect the generic drug market. The wider economic environment is also taken into account.
The report examines strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by "originator" companies to forestall generic competition.

REASONS FOR DOING THE STUDY

• This is a time of growth and change for the generic pharmaceutical sector. Major aspects that combine to create an opportunity for an up-to date market analysis include the following:
• The demand for generics is increasing steadily because of pressure to control healthcare costs. At the same time fierce price competition in this area has put some companies in difficulties because of slashed profit margins. The main result has been a wave of M&A activity, and the rise of "supergenerics" offering added value as well as low prices. Not all traditional companies are positioned to exploit this trend.
• A major growth driver for the generics sector is the fact that several blockbuster pharmaceutical brands are coming off-patent and are therefore open to generic competition — the phenomenon widely known as the "patent cliff." But the originator companies are deploying formidable strategies to protect their franchise, including marketing their own branded generics.
• With first-generation biopharmaceutical products reaching the end of their patent lives, a whole new market field — biogenerics, or biosimilars — is opening up for those generics companies capable of (or prepared to buy in) the technological expertise required.
• The international landscape is changing for generics as for all pharmaceuticals. China, India, Russia, Mexico and Brazil are among rising centers of generic activity.

SCOPE OF REPORT

This report discusses the implications of all the above-mentioned trends, in the context of the current size and growth of the generics market, both in global terms and analyzed by the most important national markets. The nature and structure of the generics industry is discussed, with profiles of the leading 20-plus generics companies, and an update on mergers and acquisitions (M&A) activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

MARKET ANALYSES AND FORECASTS

Market figures are based on revenues at the manufacturer level and are projected on the basis of 2011-dollar value without attempting to predict the effect of inflation/deflation.
Therapeutic categories quantified and forecast include antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g. hypolipidaemics and antihypertensives) and drugs for respiratory conditions including asthma and COPD.

METHODOLOGY

Primary research includes interviews with leading individuals in generics companies, industry associations and regulatory bodies. Primary sources of published data include company annual reports, SEC filings, and government and industry publications. Secondary sources consist of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC.

INTENDED AUDIENCE

This report is designed to satisfy the information needs of a wide variety of individuals involved in the generics marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.

INFORMATION SOURCES

Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also mined, as well as publications of relevant trade associations such as the Generic Pharmaceutical Association (GPhA) and the European Generic Medicines Association (EGA).

ANALYST CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of two previous reports on the generics marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

REPORT HIGHLIGHTS

The global generics sector reached $269.8 billion in 2012. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.

This report provides:
• An overview of the global market for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g., hypolipidaemics and antihypertensives), and drugs for respiratory conditions, including asthma and COPD.
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Examination of strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by "originator" companies to forestall generic competition.
• Discussion of important trends by product categories and major country markets, acknowledging that Brazil, China, India, Mexico, and Russia are among the rising markets for generic activity.
• Comprehensive profiles of leading generics companies, and updates on mergers and acquisitions.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 2
MARKET ANALYSES AND FORECASTS 3
METHODOLOGY 3
INTENDED AUDIENCE 3
INFORMATION SOURCES 3
ANALYST CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH ONLINE SERVICES 4
DISCLAIMER 4

CHAPTER 2 SUMMARY 6

MARKET SIZE AND EVOLUTION 7
SUMMARY TABLE MAJOR NATIONAL GENERIC MARKETS, THROUGH 2018 ($
BILLIONS) 8
SUMMARY FIGURE MAJOR NATIONAL GENERIC MARKETS, 2012-2018 ($ BILLIONS) 8

CHAPTER 3 OVERVIEW 10

TABLE 1 GLOBAL PHARMACEUTICAL AND GENERICS MARKETS BY REGION,
THROUGH 2018 ($ BILLIONS) 11
RECENT HISTORY OF THE GENERICS SECTOR 12
ROCHE-BOLAR 13
GENERICS LOBBY 13
ICH 14

CHAPTER 4 THE NEW GENERICS ERA 17

THE PATENT CLIFF 17
TABLE 2 MAJOR PATENT EXPIRATIONS IN 2011 AND 2012 18
TABLE 3 MAJOR PATENT EXPIRIES IN 2013 WITH PEAK BRAND SALES BEFORE
EXPIRIES 18
TABLE 4 BRAND SALES BEFORE AND AFTER PATENT EXPIRY ($ BILLIONS) 19
TYPES OF GENERICS 20
'SIMPLE' GENERICS 20
Adequate Market Size 20
Patent-expired Therapies 20
Older Products Still Used 21
Long-term Use 21
Straightforward Production Technology 21
Drugs Used in Primary Care 22
SUPERGENERICS 22
BIOSIMILARS 23
TABLE 5 BIOTHERAPEUTICS AMONG TOP 40 PRESCRIPTION PHARMACEUTICALS IN
2013 (SALES IN U.S. DOLLARS FOR Q1 2013) 24
TABLE 6 BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS, 2001-2006 26
TABLE 7 EU APPROVED BIOSIMILAR APPLICATIONS, 2012 27
Special Challenges 28
The Biosimilar Market 29
Some Biosimilar Developments and Introductions 30
EPO 30
G-CSF 30
Interferons 30
hGH 30
Monoclonal Antibodies 31

CHAPTER 5 MAJOR GENERIC ISSUES 34

REGULATORY ENVIRONMENT 34
U.S. 34
TABLE 8 REQUIREMENTS FOR NDA AND ANDA APPLICATIONS 35
EUROPEAN UNION 36
EU Marketing Authorization Systems 37
The Centralized Procedure 37
Decentralized and Mutual Recognition Procedures 38
Mutual Recognition Procedure 39
Types of Application 39
Applications under Article 10 (Generic Products) 39
JAPAN 40
Approval (Shonin) of Pharmaceuticals 41
REGULATION OF BIOSIMILARS 41
EU Provisions 41
Evolving Situation in the U.S. 42
User Fees 44
Hatch-Waxman and Bolar 44
DEFENSIVE STRATEGIES BY 'BIG PHARMA' 45
"AUTHORIZED GENERICS" 46
USER FEES 47
A CHANGING CLIMATE FOR GENERICS 48
THE SITUATION IN EUROPE 48
PATENTS AND I.P. 49
SUPPLEMENTARY PROTECTION CERTIFICATES (SPCS) 50

CHAPTER 6 THE GENERIC MARKET 53

GLOBAL PHARMACEUTICAL AND GENERICS MARKET 53
GLOBAL GENERIC MARKET 53
MAIN NATIONAL GENERICS MARKETS 53
TABLE 9 WORLD PHARMA AND GENERIC MARKETS, THROUGH 2018 ($ BILLIONS) 54
TABLE 10 CURRENT AND FORECAST NATIONAL GENERICS MARKETS, THROUGH
2018 ($ BILLIONS) 54
MARKET OPPORTUNITIES BY PRODUCT CLASS 55
LEADING GENERIC MOLECULES 55
TABLE 11 TOP 20 GENERIC MOLECULES BY PRESCRIPTION SALES, 2011 ($
BILLIONS) 55
Anti-infectives 56
TABLE 12 LEADING ANTI-INFECTIVE PRODUCTS RANKED BY SALES IN U.S.
DOLLARS FOR Q1 2013. 57
Central Nervous System Therapies 58
Antidepressants 58
Antipsychotics 59
TABLE 13 LEADING CNS PRODUCTS RANKED BY SALES IN Q1 2013 60
Anxiolytics 61
Sleep Disorders 61
Epilepsy 62
Parkinson's Disease 63
Migraine 63
Cardiovascular Products 63
TABLE 14 LEADING CARDIOVASCULAR PRODUCTS BY SALES IN Q1 2013 64
Anti-arthritis Products 65
Steroids 66
NSAIDs 66
COX-II Inhibitors 66
DMARDs 67
TABLE 15 LEADING ANTI-ARTHRITIS PRODUCTS BY SALES IN Q1 2013 67
Respiratory Products 69
Asthma 69
COPD 69
Allergic Rhinitis 69
Bronchodilators 70
Inhaled bronchodilators 70
Anticholinergics 71
Oral bronchodilators 71
Leukotriene antagonists 71
Steroids 71
FIGURE 1 GLOBAL ASTHMA MARKET BY PRODUCT, 2013 (%) 72
TABLE 16 TOP RESPIRATORY DISEASE PRODUCTS RANKED BY SALES IN Q1 2013 73
Anticancer Products 73
Cytotoxic Drugs 73
Hormonal Therapy 74
Biologic Response Modifiers 74
Antiangiogenesis Drugs 74
Monoclonal Antibodies 74
TABLE 17 LEADING ANTICANCER PRODUCTS RANKED BY SALES IN U.S. DOLLARS
FOR Q1 2013 75

CHAPTER 7 THE GLOBAL GENERICS INDUSTRY 78

TABLE 18 TOP TEN GENERICS COMPANIES, 2012 78
TRENDS 78
STRUCTURE OF THE GENERICS INDUSTRY 79
RECENT M&A ACTIVITY 80
BRAND COMPANY INVOLVEMENTS 81

CHAPTER 8 PROFILES OF TOP TEN GENERICS COMPANIES 84

ACTAVIS 84
APOTEX INC. 85
DR. REDDY'S LABORATORIES LTD. 86
ACQUISITIONS 87
FINANCIALS 88
HOSPIRA, INC. 88
BIOGENERICS 89
FINANCIALS 90
MYLAN INC. 90
FINANCIALS 92
LOOKING AHEAD 92
PAR PHARMACEUTICAL, INC. 92
GENERICS 93
FINANCIALS 94
RANBAXY LABORATORIES LIMITED 94
HISTORY 94
ACQUISITION BY DAIICHI SANKYO 95
FINANCIALS 95
LOOKING AHEAD 96
SANDOZ INTERNATIONAL GMBH 96
PRODUCTS 97
FINANCIALS 98
STADA ARZNEIMITTEL 99
GENERICS 99
BIOSIMILARS 100
FINANCIALS 100
TEVA PHARMACEUTICAL INDUSTRIES LTD 101
FINANCIALS 103
WATSON PHARMACEUTICALS INC. 103

CHAPTER 9 OTHER INTERNATIONAL GENERICS COMPANIES 105

ASPEN PHARMACARE HOLDINGS LTD 105
FINANCIAL RESULTS 106
AUROBINDO PHARMA LTD. 107
PRODUCTS 107
FINANCIALS 108
LOOKING AHEAD 108
BIOCON LTD 108
CIPLA LTD. 110
FINANCIALS 112
COBALT PHARMACEUTICALS 112
EGIS PHARMACEUTICALS PLC 113
APIS 113
PHARMACEUTICAL R&D 114
FINANCIALS 114
GEDEON RICHTER PLC. 115
GENEPHARM GROUP 116
KRKA, D. D., NOVO MESTO 117
PRODUCTS 117
FINANCIALS 118
LUPIN LTD 118
FINANCIALS 120
ORION CORPORATION 120
PRODUCTS 120
GENERICS 121
FINANCIALS 121
LOOKING AHEAD 121
PFIZER INC. 121
FINANCIALS 122
PLIVA D.D. 123
ROXANE LABORATORIES INC. 123
SANOFI 124
FINANCIALS 125
LOOKING AHEAD 125
SAWAI PHARMACEUTICAL 125
PRODUCTS 126
FINANCIALS 127
STRIDES ARCOLAB LIMITED 127
PRODUCT RANGE 128
LOOKING AHEAD 129
TANABE SEIYAKU HANBAI 129
WOCKHARDT LIMITED 130
FINANCIALS 131
ZYDUS CADILA 131
FINANCIALS 133

CHAPTER 10 THE AMERICAN REGION 135

UNITED STATES 135
VITAL STATISTICS 135
HEALTH AND HEALTHCARE 135
THE U.S. PHARMACEUTICAL MARKET 136
TABLE 19 U.S. PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018 ($
BILLIONS/%) 137
THE GENERIC MARKET: SIZE AND GROWTH 137
Biosimilars 138
Generic Prices 138
"Carve-Outs" 139
Generics Industry 139
FIGURE 2 U.S. PHARMACEUTICAL SHARES BY VALUE ($ PERCENT) AND
PERCENTAGE SHARE OF PRESCRIPTIONS, 2012 (%) 139
The Future 142
CANADA 143
VITAL STATISTICS 143
HEALTH AND HEALTHCARE 143
THE PHARMACEUTICAL MARKET 144
TABLE 20 CANADA PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018
($ BILLIONS/%) 144
GENERICS 144
Generic Prices 145
TABLE 21 LEADING PHARMA COMPANIES IN CANADA, 2011 146
Future Market Growth 146
How Generics are Supplied 147
LATIN AMERICA 147
BRAZIL 148
Vital Statistics 148
Health and Healthcare 148
Pharmaceutical Market 148
TABLE 22 PHARMACEUTICAL AND GENERICS MARKET IN BRAZIL, THROUGH 2018
($ BILLIONS/%) 149
Generic Market 150
M&A Activity 151
Background 151
ProGenericos 153
MEXICO 153
Vital Statistics 153
Health and Healthcare 154
Pharmaceutical Market 154
Generic Sector 155
TABLE 23 PHARMACEUTICAL AND GENERICS MARKET IN MEXICO, THROUGH 2018
($ BILLIONS/%) 156
Generic Industry 156
Regulatory Issues 156
AMEGI 158
Recent Developments 159

CHAPTER 11 THE ASIAN REGION 161

JAPAN 161
VITAL STATISTICS 161
HEALTH AND HEALTHCARE 161
PHARMACEUTICAL MARKET 162
TABLE 24 JAPANESE PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018
($ BILLIONS/%) 162
TABLE 25 TOP FIVE JAPANESE PHARMA COMPANIES, 2012 163
Generic Sector 164
Foreign Presence 165
Market Resistance 166
Generics Industry 166
INDIA 167
VITAL STATISTICS 167
HEALTH AND HEALTHCARE 167
Growing Affluence - Changing Medical Needs 168
Regulatory Changes 168
PHARMACEUTICAL MARKET 168
Demographic Factors 168
TABLE 26 INDIAN PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018 ($
BILLIONS/%) 170
Pharma Industry 170
Patent Reform 171
Generic Industry 171
TABLE 27 LEADING PHARMA COMPANIES IN INDIA, 2012 171
CHINA 172
VITAL STATISTICS 173
HEALTH AND HEALTHCARE 173
PHARMACEUTICAL MARKET 174
TABLE 28 PHARMACEUTICAL AND GENERIC MARKET, CHINA, THROUGH 2018 ($
BILLIONS/%) 175
Domestic Industry 175
Foreign Company Involvement 176
Importance of R&D 177
Challenges 178
Market Trends 178
Regulatory Changes 179
Generic Exports 179
Domestic Generic Market 180
Local Dominance 180
FIGURE 3 GENERIC MARKET THERAPEUTIC CATEGORIES, 2008 (%) 181

CHAPTER 12 THE EUROPEAN REGION 184

FRANCE 184
VITAL STATISTICS 184
HEALTH AND HEALTHCARE 185
Healthcare Provision 185
FIGURE 4 HEALTH EXPENDITURES IN MAJOR EUROPEAN MARKETS AND THE U.S. AS
A PERCENTAGE OF GDP, 2007 (%) 185
PHARMACEUTICAL MARKET 186
TABLE 29 PHARMACEUTICAL AND GENERIC MARKET IN FRANCE, THROUGH 2018 ($
BILLIONS/%) 187
Generic Sector 187
GERMANY 188
VITAL STATISTICS 188
HEALTH AND HEALTHCARE 188
Provision of Healthcare 189
PHARMACEUTICAL MARKET 189
TABLE 30 LEADING THERAPEUTIC CLASSES BY SALES THROUGH STATUTORY
HEALTH INSURANCE SCHEME, 2011 ($ MILLIONS) 190
Price Controls 190
TABLE 31 PHARMACEUTICAL AND GENERIC MARKET IN GERMANY, THROUGH 2018
($ BILLIONS) 191
Generics Sector 191
ITALY 192
VITAL STATISTICS 192
HEALTH AND HEALTHCARE 192
Healthcare System 193
PHARMACEUTICAL MARKET 193
Implications for Research 195
TABLE 32 SELECTED PRIORITY AREAS IN ITALY'S NATIONAL HEALTH PLAN 195
TABLE 33 PHARMACEUTICAL AND GENERIC MARKET IN ITALY, THROUGH 2018 ($
BILLIONS/%) 196
Generics Sector 196
SPAIN 197
VITAL STATISTICS 197
HEALTH AND HEALTHCARE 197
Healthcare Provision 198
Pharmaceutical Services 198
PHARMACEUTICAL MARKET 199
TABLE 34 PHARMACEUTICAL AND GENERIC MARKET IN SPAIN, THROUGH 2018 ($
BILLIONS/%) 200
Generics Sector 200
Generics Industry 200
TABLE 35 LEADING GENERICS COMPANIES IN SPAIN, 2010 201
UNITED KINGDOM 201
VITAL STATISTICS 201
HEALTH AND HEALTHCARE 202
Healthcare Provision 202
Private Sector Involvement 202
Pharmaceuticals 203
THE PHARMACEUTICAL MARKET 203
TABLE 36 LEADING PHARMA COMPANIES IN THE U.K. BY MARKET SHARE, 2011 204
The Generic Sector 205
TABLE 37 PHARMACEUTICAL AND GENERIC MARKET IN UNITED KINGDOM,
THROUGH 2018 ($ BILLIONS/%) 205
RUSSIA 205
VITAL STATISTICS 206
HEALTH AND HEALTHCARE 206
Healthcare Delivery 206
PHARMACEUTICAL MARKET 207
'Pharma 2020' 207
TABLE 38 PHARMACEUTICAL AND GENERIC MARKET IN RUSSIA, THROUGH 2018 ($
BILLIONS/%) 208
TABLE 39 LEADING PHARMA COMPANIES IN RUSSIA, BY SALES, 2012 208
Generics Sector 209

LIST OF TABLES

SUMMARY TABLE MAJOR NATIONAL GENERIC MARKETS, THROUGH 2018 ($ BILLIONS) 8
TABLE 1 GLOBAL PHARMACEUTICAL AND GENERICS MARKETS BY REGION,
THROUGH 2018 ($ BILLIONS) 11
TABLE 2 MAJOR PATENT EXPIRATIONS IN 2011 AND 2012 18
TABLE 3 MAJOR PATENT EXPIRIES IN 2013 WITH PEAK BRAND SALES BEFORE
EXPIRIES 18
TABLE 4 BRAND SALES BEFORE AND AFTER PATENT EXPIRY ($ BILLIONS) 19
TABLE 5 BIOTHERAPEUTICS AMONG TOP 40 PRESCRIPTION PHARMACEUTICALS IN
2013 (SALES IN U.S. DOLLARS FOR Q1 2013) 24
TABLE 6 BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS, 2001-2006 26
TABLE 7 EU APPROVED BIOSIMILAR APPLICATIONS, 2012 27
TABLE 8 REQUIREMENTS FOR NDA AND ANDA APPLICATIONS 35
TABLE 9 WORLD PHARMA AND GENERIC MARKETS, THROUGH 2018 ($ BILLIONS) 54
TABLE 10 CURRENT AND FORECAST NATIONAL GENERICS MARKETS, THROUGH
2018 ($ BILLIONS) 54
TABLE 11 TOP 20 GENERIC MOLECULES BY PRESCRIPTION SALES, 2011 ($ BILLIONS) 55
TABLE 12 LEADING ANTI-INFECTIVE PRODUCTS RANKED BY SALES IN U.S. DOLLARS
FOR Q1 2013. 57
TABLE 13 LEADING CNS PRODUCTS RANKED BY SALES IN Q1 2013 60
TABLE 14 LEADING CARDIOVASCULAR PRODUCTS BY SALES IN Q1 2013 64
TABLE 15 LEADING ANTI-ARTHRITIS PRODUCTS BY SALES IN Q1 2013 67
TABLE 16 TOP RESPIRATORY DISEASE PRODUCTS RANKED BY SALES IN Q1 2013 73
TABLE 17 LEADING ANTICANCER PRODUCTS RANKED BY SALES IN U.S. DOLLARS
FOR Q1 2013 75
TABLE 18 TOP TEN GENERICS COMPANIES, 2012 78
TABLE 19 U.S. PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018 ($
BILLIONS/%) 137
TABLE 20 CANADA PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018 ($
BILLIONS/%) 144
TABLE 21 LEADING PHARMA COMPANIES IN CANADA, 2011 146
TABLE 22 PHARMACEUTICAL AND GENERICS MARKET IN BRAZIL, THROUGH 2018 ($
BILLIONS/%) 149
TABLE 23 PHARMACEUTICAL AND GENERICS MARKET IN MEXICO, THROUGH 2018 ($
BILLIONS/%) 156
TABLE 24 JAPANESE PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018 ($
BILLIONS/%) 162
TABLE 25 TOP FIVE JAPANESE PHARMA COMPANIES, 2012 163
TABLE 26 INDIAN PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018 ($
BILLIONS/%) 170
TABLE 27 LEADING PHARMA COMPANIES IN INDIA, 2012 171
TABLE 28 PHARMACEUTICAL AND GENERIC MARKET, CHINA, THROUGH 2018 ($
BILLIONS/%) 175
TABLE 29 PHARMACEUTICAL AND GENERIC MARKET IN FRANCE, THROUGH 2018 ($
BILLIONS/%) 187
TABLE 30 LEADING THERAPEUTIC CLASSES BY SALES THROUGH STATUTORY
HEALTH INSURANCE SCHEME, 2011 ($ MILLIONS) 190
TABLE 31 PHARMACEUTICAL AND GENERIC MARKET IN GERMANY, THROUGH 2018
($ BILLIONS) 191
TABLE 32 SELECTED PRIORITY AREAS IN ITALY'S NATIONAL HEALTH PLAN 195
TABLE 33 PHARMACEUTICAL AND GENERIC MARKET IN ITALY, THROUGH 2018 ($
BILLIONS/%) 196
TABLE 34 PHARMACEUTICAL AND GENERIC MARKET IN SPAIN, THROUGH 2018 ($
BILLIONS/%) 200
TABLE 35 LEADING GENERICS COMPANIES IN SPAIN, 2010 201
TABLE 36 LEADING PHARMA COMPANIES IN THE U.K. BY MARKET SHARE, 2011 204
TABLE 37 PHARMACEUTICAL AND GENERIC MARKET IN UNITED KINGDOM, THROUGH
2018 ($ BILLIONS/%) 205
TABLE 38 PHARMACEUTICAL AND GENERIC MARKET IN RUSSIA, THROUGH 2018 ($
BILLIONS/%) 208
TABLE 39 LEADING PHARMA COMPANIES IN RUSSIA, BY SALES, 2012 208

LIST OF FIGURES

SUMMARY FIGURE MAJOR NATIONAL GENERIC MARKETS, 2012-2018 ($ BILLIONS) 8
FIGURE 1 GLOBAL ASTHMA MARKET BY PRODUCT, 2013 (%) 72
FIGURE 2 U.S. PHARMACEUTICAL SHARES BY VALUE ($ PERCENT) AND PERCENTAGE
SHARE OF PRESCRIPTIONS, 2012 (%) 139
FIGURE 3 GENERIC MARKET THERAPEUTIC CATEGORIES, 2008 (%) 181
FIGURE 4 HEALTH EXPENDITURES IN MAJOR EUROPEAN MARKETS AND THE U.S. AS
A PERCENTAGE OF GDP, 2007 (%) 185__

Read the full report:
Global Markets for Generic Drugs

https://www.reportbuyer.com/product/2009161/Global-Markets-for-Generic-Drugs.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As pervasive as cloud technology is -- and as persuasive as the arguments are for using it -- the cloud has its limits. Some companies will always have security concerns about storing data in the cloud and certain high-transaction applications will always be better suited for on-premises storage. Those statements were among the bottom-line takeaways delivered at Cloud Expo this week, a three day, bi-annual event focused on cloud technologies, adoption and associated challenges.
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Everyone wants to use containers, but monitoring containers is hard. New ephemeral architecture introduces new challenges in how monitoring tools need to monitor and visualize containers, so your team can make sense of everything. In his session at @DevOpsSummit, David Gildeh, co-founder and CEO of Outlyer, will go through the challenges and show there is light at the end of the tunnel if you use the right tools and understand what you need to be monitoring to successfully use containers in your...
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in compute, storage and networking technologies, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
Join IBM November 2 at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how to go beyond multi-speed it to bring agility to traditional enterprise applications. Technology innovation is the driving force behind modern business and enterprises must respond by increasing the speed and efficiency of software delivery. The challenge is that existing enterprise applications are expensive to develop and difficult to modernize. This often results in what Gartner calls ...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor – all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
“DevOps is really about the business. The business is under pressure today, competitively in the marketplace to respond to the expectations of the customer. The business is driving IT and the problem is that IT isn't responding fast enough," explained Mark Levy, Senior Product Marketing Manager at Serena Software, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...